[go: up one dir, main page]

AU2001289283A1 - Patient stratification for cancer therapy based on genomic dna microarray analysis - Google Patents

Patient stratification for cancer therapy based on genomic dna microarray analysis

Info

Publication number
AU2001289283A1
AU2001289283A1 AU2001289283A AU8928301A AU2001289283A1 AU 2001289283 A1 AU2001289283 A1 AU 2001289283A1 AU 2001289283 A AU2001289283 A AU 2001289283A AU 8928301 A AU8928301 A AU 8928301A AU 2001289283 A1 AU2001289283 A1 AU 2001289283A1
Authority
AU
Australia
Prior art keywords
genomic dna
cancer therapy
microarray analysis
dna microarray
therapy based
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001289283A
Other languages
English (en)
Inventor
Steven A. Seelig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Molecular Inc
Original Assignee
Vysis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vysis Inc filed Critical Vysis Inc
Publication of AU2001289283A1 publication Critical patent/AU2001289283A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2001289283A 2000-03-31 2001-03-29 Patient stratification for cancer therapy based on genomic dna microarray analysis Abandoned AU2001289283A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/539400 2000-03-31
US09/539,400 US9534254B1 (en) 1999-02-02 2000-03-31 Patient stratification for cancer therapy based on genomic DNA microarray analysis
PCT/US2001/010063 WO2001075160A1 (fr) 2000-03-31 2001-03-29 Stratification de patients a des fins de therapie du cancer sur la base de l'analyse de micro-reseaux d'adn genomique

Publications (1)

Publication Number Publication Date
AU2001289283A1 true AU2001289283A1 (en) 2001-10-15

Family

ID=24151048

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001289283A Abandoned AU2001289283A1 (en) 2000-03-31 2001-03-29 Patient stratification for cancer therapy based on genomic dna microarray analysis

Country Status (5)

Country Link
US (1) US9534254B1 (fr)
EP (1) EP1268860A4 (fr)
AU (1) AU2001289283A1 (fr)
CA (1) CA2402320A1 (fr)
WO (1) WO2001075160A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0878552A1 (fr) 1997-05-13 1998-11-18 Erasmus Universiteit Rotterdam Détection moléculaire d'aberration chromosomique
AU3516899A (en) 1998-05-04 1999-11-23 Dako A/S Method and probes for the detection of chromosome aberrations
JPWO2003004640A1 (ja) * 2001-07-05 2004-10-28 大鵬薬品工業株式会社 抗癌剤感受性測定用ｄｎａアレイ
KR101076146B1 (ko) * 2002-08-16 2011-10-21 렉산 팔마큐티칼스, 인크. 사람의 Ａｋｔ-1 유전자의 발현을 저해하는 안티센스 올리고뉴클레오타이드의 용도
DE03808546T1 (de) 2002-12-23 2006-01-26 Agilent Technologies, Inc., Palo Alto Vergleichende genomischehybridisierungstests unter verwendung von merkmalen immobilisierteroligonukleotide sowie zusammensetzungen zur durchführung davon
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
CA2527321A1 (fr) * 2003-05-30 2004-12-23 Genomic Health, Inc. Marqueurs d'expression genique utilises en vue d'une reaction a des medicaments inhibiteurs de egfr
US8321138B2 (en) 2005-07-29 2012-11-27 Agilent Technologies, Inc. Method of characterizing quality of hybridized CGH arrays
EP3216874A1 (fr) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Procédés pour la stratification et l'annotation des options de traitement médicamenteux contre le cancer
US20120141603A1 (en) * 2009-04-21 2012-06-07 British Columbia Cancer Agency Branch Methods and compositions for lung cancer prognosis
KR20130113447A (ko) 2010-09-24 2013-10-15 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 고정된 프라이머들을 이용하여 표적 dna의 직접적인 캡쳐, 증폭 및 서열화
WO2012095378A1 (fr) 2011-01-11 2012-07-19 Roche Diagnostics Gmbh Analyse haute résolution des courbes de fusion à titre d'outil de précriblage
CA2831922C (fr) 2011-04-01 2019-12-31 Genentech, Inc. Combinaisons de composes inhibiteurs d'akt et de vemurafenib et procedes d'utilisation
FR3078343A1 (fr) 2018-02-27 2019-08-30 Lxrepair Methode pour generer un profil des capacites de reparation de l'adn de cellules tumorales et ses applications

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5972606A (en) 1997-02-19 1999-10-26 Smithkline Beecham Corporation Human protein kinase HOACF72
US6165709A (en) * 1997-02-28 2000-12-26 Fred Hutchinson Cancer Research Center Methods for drug target screening
US6210878B1 (en) * 1997-08-08 2001-04-03 The Regents Of The University Of California Array-based detection of genetic alterations associated with disease
AU756731C (en) * 1998-02-25 2004-07-29 Canton Of Basel-Stadt Cellular arrays for rapid molecular profiling
US6004755A (en) 1998-04-07 1999-12-21 Incyte Pharmaceuticals, Inc. Quantitative microarray hybridizaton assays
US6111092A (en) * 1998-06-03 2000-08-29 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding DRT111 and uses thereof
US6251601B1 (en) 1999-02-02 2001-06-26 Vysis, Inc. Simultaneous measurement of gene expression and genomic abnormalities using nucleic acid microarrays

Also Published As

Publication number Publication date
CA2402320A1 (fr) 2001-10-11
US9534254B1 (en) 2017-01-03
EP1268860A1 (fr) 2003-01-02
WO2001075160A1 (fr) 2001-10-11
EP1268860A4 (fr) 2007-05-30

Similar Documents

Publication Publication Date Title
IL148783A0 (en) Methods for genomic analysis
AU2002352799A8 (en) Methods for evaluating drug-resistance gene expression in the cancer patient
AU2003291481A1 (en) Methods for identifying dna copy number changes
AU2002305436A1 (en) Multiple sequencible and ligatible structures for genomic analysis
AU2003212954A1 (en) Skin cell biomarkers and methods for identifying biomarkers using nucleic acid microarrays
AU2002361908A1 (en) Methods for identifying marker genes for cancer
GB0119719D0 (en) DNA sequence analysis
AU2001289283A1 (en) Patient stratification for cancer therapy based on genomic dna microarray analysis
AU2001294943A1 (en) Nucleic acid sequences differentially expressed in cancer tissue
AU2002341717A1 (en) Cell therapy system
AU6458400A (en) Nucleic acid, polypeptides, assays, therapeutic methods and means
AU2003303869A1 (en) Methods for nucleic acid analysis
AU2003296087A1 (en) Nucleotide derivatives and dna microarray
AU2003283339A1 (en) Cancer therapy determination
AU5049001A (en) Dna analysis
AU3269401A (en) Simultaneous hybridization/priming for snp analysis
AU2001257448A1 (en) Use of representations of dna for genetic analysis
IL159975A0 (en) Stain-directed molecular analysis for cancer prognosis and diagnosis
AU1457300A (en) Dna replication-regulating genes, antibodies thereto and diagnostic applicationsthereof
WO2003025198A3 (fr) Polymorphismes regulateurs d'un nucleotide simple et procedes associes
AU2002322013A1 (en) Therapeutic dna vaccination
AU2002364883A1 (en) Means for identifying neisseiria menengitidis specific genes
AU2002353189A1 (en) Improvements in dna profile analysis
AU2002243307A1 (en) Gene therapy using tgf-beta
AU2001290565A1 (en) Isolated human drug-metabolizing proteins, nucleic acid moleculesand uses thereof